NCT05800015: An ongoing trial by Regeneron Pharmaceuticals
This trial is ongoing. It must report results 5 years, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05800015 |
|---|---|
| Title | A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 8, 2023 |
| Completion date | Jan. 16, 2030 |
| Required reporting date | Jan. 16, 2031, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |